Breast Cancer

**Pre-Op Therapy**
- No Trial Currently Available

**Surgical Therapy**
- No Trial Currently Available

**Adjuvant Therapy**
- No Trial Currently Available

**1st line MBC Therapy**
- IRB#16300 - A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer
- IRB#9076 - Phase III study in postmenopausal women that have progressed on or after mTOR therapy
- IRB#11351 - Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer
- IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
- IRB#11351 - Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer

**2nd line MBC Therapy**
- No Trial Currently Available

**3rd line MBC Therapy**
- No Trial Currently Available

**“Heavily Pre-treated” Therapy**
- No Trial Currently Available

**Endocrine Therapy**
- ER/PR-POSITIVE HER2 NEGATIVE
- No Trial Currently Available
- IRB#6256 - ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

**HER2 Positive**
- IRB#9340 - Phase II breast conservation surgery and radiation therapy study
- No Trial Currently Available
- IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1st line and beyond HER2 + MBC therapy)
- IRB#11351 - Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer

**“TRIPLE NEGATIVE” EP/PR–NEGATIVE HER2-NEGATIVE**
- IRB#15176 - A Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)
- IRB#9076 - A Phase II breast conservation surgery and radiation therapy study

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

2/14/2017